Literature DB >> 17699164

More about the "ARB MI paradox".

Alistair S Hall, Martin H Strauss.   

Abstract

"Logic dictates that angiotensin converting enzyme inhibitors should remain the preferred drug across the entire spectrum of cardiometabolic disease"

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17699164      PMCID： PMC1955006          DOI： 10.1136/hrt.2006.107185

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


  13 in total

1.  Angiotensin-receptor blockade in acute myocardial infarction--a matter of dose.

Authors:  Douglas L Mann; Anita Deswal
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245

2.  Angiotensin receptor blockers and myocardial infarction: the importance of dosage.

Authors:  Riccardo Sarzani; Paolo Dessì-Fulgheri
Journal:  J Hypertens       Date:  2006-08       Impact factor: 4.844

3.  Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention.

Authors:  Paolo Verdecchia; Gianpaolo Reboldi; Fabio Angeli; Roberto Gattobigio; Maurizio Bentivoglio; Lutgarde Thijs; Jan A Staessen; Carlo Porcellati
Journal:  Hypertension       Date:  2005-07-11       Impact factor: 10.190

4.  Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators.

Authors:  R S McKelvie; S Yusuf; D Pericak; A Avezum; R J Burns; J Probstfield; R T Tsuyuki; M White; J Rouleau; R Latini; A Maggioni; J Young; J Pogue
Journal:  Circulation       Date:  1999-09-07       Impact factor: 29.690

5.  Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

Authors:  Joachim Schrader; Stephan Lüders; Anke Kulschewski; Frank Hammersen; Kerstin Plate; Jürgen Berger; Walter Zidek; Peter Dominiak; Hans Christoph Diener
Journal:  Stroke       Date:  2005-05-05       Impact factor: 7.914

6.  Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial.

Authors:  Michael A Weber; Stevo Julius; Sverre E Kjeldsen; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John H Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; M Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

7.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

8.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245

9.  The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design.

Authors:  J Mann; S Julius
Journal:  Blood Press       Date:  1998-05       Impact factor: 2.835

10.  Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system.

Authors:  F Turnbull; B Neal; M Pfeffer; J Kostis; C Algert; M Woodward; J Chalmers; A Zanchetti; S MacMahon
Journal:  J Hypertens       Date:  2007-05       Impact factor: 4.844
View more
  2 in total

1.  Risk of cancer with angiotensin-receptor blockers increases with increasing cumulative exposure: Meta-regression analysis of randomized trials.

Authors:  Ilke Sipahi
Journal:  PLoS One       Date:  2022-03-02       Impact factor: 3.240

Review 2.  Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses.

Authors:  Ferrán Catalá-López; Diego Macías Saint-Gerons; Diana González-Bermejo; Giuseppe M Rosano; Barry R Davis; Manuel Ridao; Abel Zaragoza; Dolores Montero-Corominas; Aurelio Tobías; César de la Fuente-Honrubia; Rafael Tabarés-Seisdedos; Brian Hutton
Journal:  PLoS Med       Date:  2016-03-08       Impact factor: 11.069
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.